Published in J Endovasc Ther on February 01, 2007
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
The risk of recurrent venous thromboembolism in men and women. N Engl J Med (2004) 7.41
Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65
Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med (2006) 6.51
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med (2008) 3.87
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med (2004) 3.63
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
D-dimer levels and risk of recurrent venous thromboembolism. JAMA (2003) 3.30
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil (2005) 3.17
Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation (2006) 3.08
Does carotid stent cell design matter? Stroke (2008) 3.02
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97
Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell (2010) 2.91
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol (2002) 2.88
Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation (2007) 2.80
Bivalirudin started during emergency transport for primary PCI. N Engl J Med (2013) 2.80
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging (2013) 2.47
Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation (2006) 2.46
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 2.36
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med (2004) 2.27
Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J (2004) 2.11
Gender differences in outcome of conservatively treated patients with asymptomatic high grade carotid stenosis. Stroke (2005) 2.10
Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev (2014) 2.08
Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci (2004) 2.08
Effect of smoking on restenosis during the 1st year after lower-limb endovascular interventions. Radiology (2004) 2.07
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03
Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation (2004) 2.03
Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol (2002) 2.02
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol (2009) 1.98
Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med (2004) 1.98
Benefit of atrial septal defect closure in adults: impact of age. Eur Heart J (2010) 1.94
Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis (2005) 1.94
Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv (2009) 1.90
Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation (2005) 1.89
Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88
Hypotension and bradycardia after elective carotid stenting: frequency and risk factors. J Endovasc Ther (2003) 1.85
Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res (2006) 1.84
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81
D-dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J (2007) 1.79
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest (2013) 1.72
Renal artery PTA and stent implantation: immediate and late clinical and morphological outcome. Wien Klin Wochenschr (2002) 1.69